In addition, the use of monoclonal antibodies against IgE and IL5 such as omalizumab and mepolizumab, respectively, has shown promising results in the treatment of patients with eosinophilic gastroenteritis in clinical trials [9, 12]. Here, IL5 is linked to eosinophilic gastroenteritis.